The label for Jardiance (empagliflozin) was updated on 2026-06-17 to include new indications for heart failure and kidney disease. Specifically, Jardiance is now indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. Furthermore, it is indicated to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease.
Background
Empagliflozin, marketed as Jardiance, is a medication that can also be found in several combination products. These include Synjardy XR, Glyxambi, Synjardy, and Trijardy XR. These combination therapies incorporate other active ingredients such as metformin hydrochloride and linagliptin, which are also listed as related drugs.
What this means
The updated label for Jardiance significantly expands its therapeutic utility, providing clinicians with a broader scope for its prescription. The new indications specifically address critical patient populations: adults with heart failure and adults with chronic kidney disease. For heart failure patients, Jardiance is now indicated to reduce the risk of serious outcomes including cardiovascular death and hospitalization. For patients with chronic kidney disease, the label highlights its role in reducing the risk of sustained decline in eGFR, progression to end-stage kidney disease, cardiovascular death, and hospitalization. This update underscores the drug's potential to improve outcomes across these interconnected cardiovascular and renal conditions.
Source
The information regarding this label revision was obtained from the FDA, as documented on DailyMed. The revised label for Jardiance became effective on 2026-06-17, and is accessible via dailymed.nlm.nih.gov.